Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of Ascending Doses of AZD9291 (osimertinib) in Patients with Advanced Non-small Cell Lung Cancer who have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Agent (AURA)

    Summary
    EudraCT number
    2012-004628-39
    Trial protocol
    GB   DE   IT  
    Global end of trial date
    11 Dec 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    26 Dec 2024
    First version publication date
    26 Dec 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    D5160C00001
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    AstraZeneca
    Sponsor organisation address
    Melbourn Science Park, Cambridge Street, Melbourn, United Kingdom, SG8 6EE
    Public contact
    Senior Medical Director, Tagrisso, AstraZeneca, ClinicalTrialTransparency@astrazeneca.com
    Scientific contact
    Senior Medical Director, Tagrisso, AstraZeneca, ClinicalTrialTransparency@astrazeneca.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    01 May 2018
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    11 Dec 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of the AURA study was to investigate the safety, tolerability, and efficacy (objective response rate [ORR]) of osimertinib when given orally to patients with locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC) who have progressed following prior therapy with an Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) agent .
    Protection of trial subjects
    The study was performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with International Conference on Harmonisation / Good Clinical Practice, applicable regulatory requirements and the AstraZeneca policy on Bioethics and Human Biological Samples.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    06 Mar 2013
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Australia: 27
    Country: Number of subjects enrolled
    France: 29
    Country: Number of subjects enrolled
    Germany: 31
    Country: Number of subjects enrolled
    Italy: 14
    Country: Number of subjects enrolled
    Japan: 102
    Country: Number of subjects enrolled
    Korea, Republic of: 142
    Country: Number of subjects enrolled
    Spain: 37
    Country: Number of subjects enrolled
    Taiwan: 97
    Country: Number of subjects enrolled
    United Kingdom: 18
    Country: Number of subjects enrolled
    United States: 106
    Worldwide total number of subjects
    603
    EEA total number of subjects
    111
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    378
    From 65 to 84 years
    219
    85 years and over
    6

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Patients recruited to different cohorts. Dose escalation cohort of pre-treated patients in 5 dose groups. Dose expansion cohort (pre-treated) in same 5 dose groups. First line patient cohort. 80mg tablet cohort of pre-treated patients. Japan-only cohort (EGFR T790M+ by cytology). Phase II extension cohort in pre-treated EGFR T790M+ patients.

    Pre-assignment
    Screening details
    603 patients were enrolled and received treatment.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    AZD9291 80mg Extension
    Arm description
    Phase II dose extension cohort in pre-treated EGFR T790M mutation positive patients in AZD9291 80mg tablet.
    Arm type
    Experimental

    Investigational medicinal product name
    TAGRISSO
    Investigational medicinal product code
    AZD9291
    Other name
    Pharmaceutical forms
    Coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    80mg oral

    Arm title
    Dose escalation
    Arm description
    Pre-treated patient cohort in doses 20, 40, 80, 160 and 240mg AZD9291 capsule.
    Arm type
    Experimental

    Investigational medicinal product name
    TAGRISSO
    Investigational medicinal product code
    AZD9291
    Other name
    Pharmaceutical forms
    Capsule, soft
    Routes of administration
    Oral use
    Dosage and administration details
    20-240mg oral

    Arm title
    Dose expansion
    Arm description
    Pre-treated EGFR T790M mutation positive (by central testing) patient cohort. Dose groups were expanded to include more patients.
    Arm type
    Experimental

    Investigational medicinal product name
    TAGRISSO
    Investigational medicinal product code
    AZD9291
    Other name
    Pharmaceutical forms
    Coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    20-240mg oral

    Arm title
    First line
    Arm description
    Cohort of patients receiving first-line treatment for EGFRm advanced NSCLC, in 80mg and 160mg AZD9291 capsule.
    Arm type
    Experimental

    Investigational medicinal product name
    TAGRISSO
    Investigational medicinal product code
    AZD9291
    Other name
    Pharmaceutical forms
    Coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    80-160mg oral

    Arm title
    80mg tablet
    Arm description
    US-only cohort of pre-treated EGFR patients receiving the tablet formulation of AZD9291 (80 mg).
    Arm type
    Experimental

    Investigational medicinal product name
    TAGRISSO
    Investigational medicinal product code
    AZD9291
    Other name
    Pharmaceutical forms
    Coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    80mg oral

    Arm title
    Japan cytology
    Arm description
    Japan-only cohort of patients (EGFR T790M mutation status determined from cytology samples) receiving AZD9291 80 mg tablet.
    Arm type
    Experimental

    Investigational medicinal product name
    TAGRISSO
    Investigational medicinal product code
    AZD9291
    Other name
    Pharmaceutical forms
    Coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    80mg oral

    Number of subjects in period 1
    AZD9291 80mg Extension Dose escalation Dose expansion First line 80mg tablet Japan cytology
    Started
    201
    31
    271
    60
    12
    28
    Completed
    0
    0
    0
    0
    0
    0
    Not completed
    201
    31
    271
    60
    12
    28
         Adverse event, serious fatal
    135
    5
    52
    5
    4
    2
         Consent withdrawn by subject
    15
    2
    15
    5
    1
    1
         Terminated due to study closure
    46
    -
    -
    11
    -
    -
         Objective Disease Progression
    -
    18
    164
    35
    7
    17
         Other (not specified)
    1
    -
    8
    3
    -
    1
         Lost to follow-up
    4
    -
    -
    1
    -
    -
         Ongoing Study at Data Cut-off
    -
    6
    32
    -
    -
    7

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    AZD9291 80mg Extension
    Reporting group description
    Phase II dose extension cohort in pre-treated EGFR T790M mutation positive patients in AZD9291 80mg tablet.

    Reporting group title
    Dose escalation
    Reporting group description
    Pre-treated patient cohort in doses 20, 40, 80, 160 and 240mg AZD9291 capsule.

    Reporting group title
    Dose expansion
    Reporting group description
    Pre-treated EGFR T790M mutation positive (by central testing) patient cohort. Dose groups were expanded to include more patients.

    Reporting group title
    First line
    Reporting group description
    Cohort of patients receiving first-line treatment for EGFRm advanced NSCLC, in 80mg and 160mg AZD9291 capsule.

    Reporting group title
    80mg tablet
    Reporting group description
    US-only cohort of pre-treated EGFR patients receiving the tablet formulation of AZD9291 (80 mg).

    Reporting group title
    Japan cytology
    Reporting group description
    Japan-only cohort of patients (EGFR T790M mutation status determined from cytology samples) receiving AZD9291 80 mg tablet.

    Reporting group values
    AZD9291 80mg Extension Dose escalation Dose expansion First line 80mg tablet Japan cytology Total
    Number of subjects
    201 31 271 60 12 28 603
    Age, Customized
    Units: Subjects
        <50 Years|
    30 3 42 8 3 3 89
        >=50-<65 Years|
    86 19 142 23 6 13 289
        >=65-<75 Years|
    64 8 59 22 3 9 165
        >=75 Years|
    21 1 28 7 0 3 60
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    61.4 ( 10.58 ) 59.8 ( 8.8 ) 60.0 ( 10.7 ) 62.1 ( 10.8 ) 57.6 ( 9.8 ) 62.4 ( 9.7 ) -
    Gender, Male/Female
    Units: Subjects
        Female
    133 20 167 45 8 21 394
        Male
    68 11 104 15 4 7 209
    Race, Customized
    Units: Subjects
        Asian|
    114 21 160 43 4 28 370
        Black Or African American|
    1 0 3 0 1 0 5
        Missing|
    2 0 0 0 0 0 2
        Not Reported|
    4 4 11 1 0 0 20
        Other|
    4 0 0 0 0 0 4
        White|
    76 6 96 15 7 0 200
        American Indian or Alaska Native|
    0 0 1 1 0 0 2

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    AZD9291 80mg Extension
    Reporting group description
    Phase II dose extension cohort in pre-treated EGFR T790M mutation positive patients in AZD9291 80mg tablet.

    Reporting group title
    Dose escalation
    Reporting group description
    Pre-treated patient cohort in doses 20, 40, 80, 160 and 240mg AZD9291 capsule.

    Reporting group title
    Dose expansion
    Reporting group description
    Pre-treated EGFR T790M mutation positive (by central testing) patient cohort. Dose groups were expanded to include more patients.

    Reporting group title
    First line
    Reporting group description
    Cohort of patients receiving first-line treatment for EGFRm advanced NSCLC, in 80mg and 160mg AZD9291 capsule.

    Reporting group title
    80mg tablet
    Reporting group description
    US-only cohort of pre-treated EGFR patients receiving the tablet formulation of AZD9291 (80 mg).

    Reporting group title
    Japan cytology
    Reporting group description
    Japan-only cohort of patients (EGFR T790M mutation status determined from cytology samples) receiving AZD9291 80 mg tablet.

    Primary: Objective Response Rate (ORR) for dose expansion population

    Close Top of page
    End point title
    Objective Response Rate (ORR) for dose expansion population [1] [2]
    End point description
    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): >= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. ORR is the percentage of patients with at least 1 visit response of CR or PR (by investigator assessment) that was confirmed at least 4 weeks later, prior to progression or further anti-cancer therapy.
    End point type
    Primary
    End point timeframe
    RECIST tumour assessments every 6 weeks from randomisation until objective disease progression, up to approximately 21 months (at time of analysis)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical hypothesis to be tested. Descriptive statistics are produced.
    [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: No statistical hypothesis to be tested. Descriptive statistics are produced.
    End point values
    Dose expansion
    Number of subjects analysed
    175 [3]
    Units: % of participants
        number (confidence interval 95%)
    64.0 (56.4 to 71.1)
    Notes
    [3] - Patients who are T790m+ve
    No statistical analyses for this end point

    Primary: Best Objective Response (BOR) for dose escalation population

    Close Top of page
    End point title
    Best Objective Response (BOR) for dose escalation population [4] [5]
    End point description
    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): >= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions; Stable disease (SD): Neither sufficient shrinkage to qualify as a response nor sufficient growth to qualify as progression; Progressive Disease (PD): >= 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of >=5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. Not evaluable (NE): TL response is missing and there is no evidence of progression of NTLs and no new lesions. BOR is the best response (by investigator assessment) a patient has achieved where the order of best to worst is CR, PR, SD, PD, NE prior to or at progression and prior to further anti-cancer therapy.
    End point type
    Primary
    End point timeframe
    RECIST tumour assessments every 6 weeks from randomisation until objective disease progression, up to approximately 25 months (at time of analysis)
    Notes
    [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical hypothesis to be tested. Descriptive statistics are produced.
    [5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: No statistical hypothesis to be tested. Descriptive statistics are produced.
    End point values
    Dose escalation
    Number of subjects analysed
    31
    Units: Number of participants
        Partial Response|
    19
        Stable disease|
    5
        Progressive disease|
    5
        Not evaluable|
    2
    No statistical analyses for this end point

    Primary: Objective Response Rate (ORR) for extension population

    Close Top of page
    End point title
    Objective Response Rate (ORR) for extension population [6] [7]
    End point description
    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): >= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. ORR is the percentage of patients with at least 1 visit response of CR or PR (by independent central review) that was confirmed at least 4 weeks later, prior to progression or further anti-cancer therapy.
    End point type
    Primary
    End point timeframe
    RECIST tumour assessments every 6 weeks from randomisation until objective disease progression, up to approximately 12 months (at the time of analysis)
    Notes
    [6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical hypothesis to be tested. Descriptive statistics are produced.
    [7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: No statistical hypothesis to be tested. Descriptive statistics are produced.
    End point values
    AZD9291 80mg Extension
    Number of subjects analysed
    198 [8]
    Units: % of participants
        number (confidence interval 95%)
    61.1 (53.9 to 67.9)
    Notes
    [8] - Some patients do not have baseline measurable lesions
    No statistical analyses for this end point

    Primary: Objective Response Rate (ORR) for 1st line population

    Close Top of page
    End point title
    Objective Response Rate (ORR) for 1st line population [9] [10]
    End point description
    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): >= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. ORR is the percentage of patients with at least 1 visit response of CR or PR (by investigator assessment) that was confirmed at least 4 weeks later, prior to progression or further anti-cancer therapy.
    End point type
    Primary
    End point timeframe
    RECIST tumour assessments every 6 weeks from randomisation until objective disease progression, up to approximately 21 months (at time of analysis)
    Notes
    [9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical hypothesis to be tested. Descriptive statistics are produced.
    [10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: No statistical hypothesis to be tested. Descriptive statistics are produced.
    End point values
    First line
    Number of subjects analysed
    60
    Units: % of participants
        number (confidence interval 95%)
    76.7 (64.0 to 86.6)
    No statistical analyses for this end point

    Secondary: Duration of Response (DoR) for dose expansion population

    Close Top of page
    End point title
    Duration of Response (DoR) for dose expansion population [11]
    End point description
    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): >= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. DoR was defined as the time from the date of first documented response (CR or PR that was subsequently confirmed) until the date of documented progression (PD) or death in the absence of disease progression (by investigator assessment).
    End point type
    Secondary
    End point timeframe
    RECIST tumour assessments every 6 weeks from randomisation until objective disease progression, up to approximately 21 months (at time of analysis)
    Notes
    [11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: No statistical hypothesis to be tested. Descriptive statistics are produced.
    End point values
    Dose expansion
    Number of subjects analysed
    112
    Units: months
        median (confidence interval 95%)
    9.7 (8.4 to 13.7)
    No statistical analyses for this end point

    Secondary: Progression-Free Survival (PFS) for dose expansion population

    Close Top of page
    End point title
    Progression-Free Survival (PFS) for dose expansion population [12]
    End point description
    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Progressive Disease (PD): >= 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of >=5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. PFS is the time from date of first dose until the date of PD (by independent central review) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from AZD9291 therapy or received another anti-cancer therapy prior to progression. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST 1.1 assessment.
    End point type
    Secondary
    End point timeframe
    RECIST tumour assessments every 6 weeks from randomisation until objective disease progression, up to approximately 21 months (at time of analysis)
    Notes
    [12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: No statistical hypothesis to be tested. Descriptive statistics are produced.
    End point values
    Dose expansion
    Number of subjects analysed
    182
    Units: months
        median (confidence interval 95%)
    9.6 (8.3 to 11.0)
    No statistical analyses for this end point

    Secondary: Progression-Free Survival (PFS) for 1st line population

    Close Top of page
    End point title
    Progression-Free Survival (PFS) for 1st line population [13]
    End point description
    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Progressive Disease (PD): >= 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of >=5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. PFS is the time from date of first dose until the date of PD (by independent central review) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from AZD9291 therapy or received another anti-cancer therapy prior to progression. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST 1.1 assessment.
    End point type
    Secondary
    End point timeframe
    RECIST tumour assessments every 6 weeks from randomisation until objective disease progression, up to approximately 21 months (at time of analysis)
    Notes
    [13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: No statistical hypothesis to be tested. Descriptive statistics are produced.
    End point values
    First line
    Number of subjects analysed
    60
    Units: months
        median (confidence interval 95%)
    20.5 (13.7 to 26.1)
    No statistical analyses for this end point

    Secondary: Duration of Response (DoR) for 1st line population

    Close Top of page
    End point title
    Duration of Response (DoR) for 1st line population [14]
    End point description
    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Progressive Disease (PD): >= 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of >=5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. PFS is the time from date of first dose until the date of PD (by independent central review) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from AZD9291 therapy or received another anti-cancer therapy prior to progression. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST 1.1 assessment.
    End point type
    Secondary
    End point timeframe
    RECIST tumour assessments every 6 weeks from randomisation until objective disease progression, up to approximately 21 months (at time of analysis)
    Notes
    [14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: No statistical hypothesis to be tested. Descriptive statistics are produced.
    End point values
    First line
    Number of subjects analysed
    46 [15]
    Units: months
        median (confidence interval 95%)
    18.0 (12.5 to 24.7)
    Notes
    [15] - 46 patients responded as per RECIST v 1.1
    No statistical analyses for this end point

    Secondary: Overall Survival (OS) for 80mg AZD9291 extension population

    Close Top of page
    End point title
    Overall Survival (OS) for 80mg AZD9291 extension population [16]
    End point description
    OS is the time from date of first dose until the date of death (by any cause). Patients who had not died at the time of analysis were censored at the time they were last known to be alive.
    End point type
    Secondary
    End point timeframe
    From randomisation until death, up to approximately 21 months (at time of analysis)
    Notes
    [16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: No statistical hypothesis to be tested. Descriptive statistics are produced.
    End point values
    AZD9291 80mg Extension
    Number of subjects analysed
    201
    Units: months
        median (confidence interval 95%)
    24.3 (21.2 to 28.8)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    AEs from start of study drug until 28 days post treatment discontinuation, up to DCO
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    19.1, 21.0
    Reporting groups
    Reporting group title
    AZD9291 80mg
    Reporting group description
    Description (Arm-group)

    Reporting group title
    Dose escalation
    Reporting group description
    Description (Arm-group)

    Reporting group title
    Japan cytology
    Reporting group description
    Description (Arm-group)

    Reporting group title
    First Line
    Reporting group description
    Description (Arm-group)

    Reporting group title
    80mg Tablet
    Reporting group description
    Description (Arm-group)

    Reporting group title
    Dose expansion
    Reporting group description
    Description (Arm-group)

    Serious adverse events
    AZD9291 80mg Dose escalation Japan cytology First Line 80mg Tablet Dose expansion
    Total subjects affected by serious adverse events
         subjects affected / exposed
    85 / 201 (42.29%)
    12 / 31 (38.71%)
    5 / 28 (17.86%)
    27 / 60 (45.00%)
    5 / 12 (41.67%)
    103 / 271 (38.01%)
         number of deaths (all causes)
    135
    5
    2
    5
    4
    54
         number of deaths resulting from adverse events
    11
    1
    0
    1
    2
    13
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Breast cancer
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lymphoma
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Follicular thyroid cancer
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Endometrial cancer stage i
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diffuse large b-cell lymphoma
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Colon cancer
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cancer pain
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metastases to central nervous system
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Uterine leiomyoma
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tumour pain
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Prostate cancer
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Aortic intramural haematoma
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Deep vein thrombosis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Embolism
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haematoma
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Peripheral artery thrombosis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Death
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fatigue
         subjects affected / exposed
    1 / 201 (0.50%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oedema peripheral
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General physical health deterioration
         subjects affected / exposed
    0 / 201 (0.00%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Localised oedema
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Malaise
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    1 / 28 (3.57%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gait disturbance
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Immune system disorders
    Anaphylactic reaction
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Benign prostatic hyperplasia
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Acquired tracheo-oesophageal fistula
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Pneumonia aspiration
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pleural effusion
         subjects affected / exposed
    3 / 201 (1.49%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Interstitial lung disease
         subjects affected / exposed
    3 / 201 (1.49%)
    0 / 31 (0.00%)
    1 / 28 (3.57%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    3 / 3
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypoxia
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dyspnoea
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    7 / 271 (2.58%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 7
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    Asthma
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonitis
         subjects affected / exposed
    3 / 201 (1.49%)
    0 / 31 (0.00%)
    2 / 28 (7.14%)
    3 / 60 (5.00%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences causally related to treatment / all
    3 / 3
    0 / 0
    2 / 2
    2 / 3
    0 / 0
    3 / 3
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Pneumothorax
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumothorax spontaneous
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary artery thrombosis
         subjects affected / exposed
    0 / 201 (0.00%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    5 / 201 (2.49%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    4 / 60 (6.67%)
    0 / 12 (0.00%)
    12 / 271 (4.43%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 1
    0 / 0
    0 / 5
    0 / 0
    3 / 17
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary granuloma
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary hypertension
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory failure
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Delirium
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Confusional state
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Completed suicide
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    Anxiety
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Adjustment disorder with depressed mood
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Delusion
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Depression
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Suicide attempt
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    Insomnia
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Investigations
    Amylase increased
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Alanine aminotransferase increased
         subjects affected / exposed
    0 / 201 (0.00%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Aspartate aminotransferase increased
         subjects affected / exposed
    0 / 201 (0.00%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Platelet count decreased
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neutrophil count decreased
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lipase increased
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemoglobin decreased
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood bilirubin increased
         subjects affected / exposed
    1 / 201 (0.50%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Limb injury
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thoracic vertebral fracture
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ankle fracture
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fall
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hip fracture
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Traumatic fracture
         subjects affected / exposed
    3 / 201 (1.49%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    2 / 60 (3.33%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Subdural haematoma
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    2 / 60 (3.33%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal fracture
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Road traffic accident
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Post procedural complication
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Overdose
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Stress cardiomyopathy
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myocardial infarction
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Angina pectoris
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac failure acute
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac failure congestive
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulseless electrical activity
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    Atrial fibrillation
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    1 / 2
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Aphasia
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral cyst
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral haemorrhage
         subjects affected / exposed
    1 / 201 (0.50%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral infarction
         subjects affected / exposed
    3 / 201 (1.49%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral ischaemia
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cognitive disorder
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebrovascular accident
         subjects affected / exposed
    3 / 201 (1.49%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebrospinal fluid retention
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Embolic stroke
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hemiparesis
         subjects affected / exposed
    0 / 201 (0.00%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Headache
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Facial nerve disorder
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Epilepsy
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intracranial haematoma
         subjects affected / exposed
    0 / 201 (0.00%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ischaemic stroke
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Monoplegia
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Seizure
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Presyncope
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Partial seizures
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorder
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Transient ischaemic attack
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Aplastic anaemia
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Microcytic anaemia
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Disseminated intravascular coagulation
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Febrile neutropenia
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancytopenia
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thrombocytopenia
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    1 / 28 (3.57%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eye disorders
    Corneal erosion
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal pain upper
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Food poisoning
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Constipation
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    2 / 201 (1.00%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    3 / 60 (5.00%)
    0 / 12 (0.00%)
    4 / 271 (1.48%)
         occurrences causally related to treatment / all
    1 / 2
    1 / 1
    0 / 0
    1 / 3
    0 / 0
    2 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dysphagia
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Colitis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastric ulcer
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastritis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal obstruction
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Inguinal hernia
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haematemesis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemorrhoids
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrooesophageal reflux disease
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nausea
         subjects affected / exposed
    1 / 201 (0.50%)
    2 / 31 (6.45%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences causally related to treatment / all
    0 / 1
    2 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oesophageal stenosis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    1 / 201 (0.50%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 1
    0 / 0
    0 / 1
    0 / 0
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancreatitis
         subjects affected / exposed
    1 / 201 (0.50%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rectal haemorrhage
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Small intestine ulcer
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oesophagitis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholangitis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholecystitis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Jaundice
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatic function abnormal
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Skin toxicity
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Subcutaneous emphysema
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Renal impairment
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal failure
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Hydronephrosis
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute kidney injury
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    1 / 28 (3.57%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Costochondritis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal column stenosis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rotator cuff syndrome
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pathological fracture
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pain in extremity
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal chest pain
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Bronchitis
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atypical pneumonia
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia bacterial
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyelonephritis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    1 / 28 (3.57%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    4 / 271 (1.48%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Viraemia
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abscess
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal infection
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Appendicitis
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bacteraemia
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bacterial sepsis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Escherichia urinary tract infection
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Device related infection
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diarrhoea infectious
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Erysipelas
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Influenza
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    2 / 60 (3.33%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Klebsiella infection
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lower respiratory tract infection
         subjects affected / exposed
    0 / 201 (0.00%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia viral
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mediastinitis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    9 / 201 (4.48%)
    4 / 31 (12.90%)
    0 / 28 (0.00%)
    5 / 60 (8.33%)
    0 / 12 (0.00%)
    13 / 271 (4.80%)
         occurrences causally related to treatment / all
    0 / 11
    1 / 4
    0 / 0
    0 / 5
    0 / 0
    0 / 13
         deaths causally related to treatment / all
    0 / 1
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 6
    Pneumonia pneumococcal
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lung infection
         subjects affected / exposed
    1 / 201 (0.50%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    Post procedural infection
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyelonephritis acute
         subjects affected / exposed
    0 / 201 (0.00%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory tract infection
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Septic shock
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    Rhinovirus infection
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Salmonella sepsis
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory tract infection bacterial
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    Streptococcal bacteraemia
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Subperiosteal abscess
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Upper respiratory tract infection
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection bacterial
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Viral infection
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    1 / 201 (0.50%)
    2 / 31 (6.45%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    1 / 1
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypercalcaemia
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypoglycaemia
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dehydration
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypokalaemia
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyponatraemia
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    AZD9291 80mg Dose escalation Japan cytology First Line 80mg Tablet Dose expansion
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    199 / 201 (99.00%)
    31 / 31 (100.00%)
    26 / 28 (92.86%)
    60 / 60 (100.00%)
    12 / 12 (100.00%)
    267 / 271 (98.52%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Metastases to central nervous system
         subjects affected / exposed
    1 / 201 (0.50%)
    2 / 31 (6.45%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    1
    3
    0
    0
    0
    0
    Vascular disorders
    Deep vein thrombosis
         subjects affected / exposed
    4 / 201 (1.99%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    2 / 60 (3.33%)
    1 / 12 (8.33%)
    10 / 271 (3.69%)
         occurrences all number
    4
    1
    0
    2
    1
    12
    Hypertension
         subjects affected / exposed
    10 / 201 (4.98%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    4 / 60 (6.67%)
    2 / 12 (16.67%)
    10 / 271 (3.69%)
         occurrences all number
    10
    1
    0
    6
    2
    11
    Thrombosis
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences all number
    2
    0
    0
    0
    1
    0
    Hypotension
         subjects affected / exposed
    5 / 201 (2.49%)
    1 / 31 (3.23%)
    1 / 28 (3.57%)
    2 / 60 (3.33%)
    2 / 12 (16.67%)
    4 / 271 (1.48%)
         occurrences all number
    6
    1
    1
    2
    2
    4
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    32 / 201 (15.92%)
    7 / 31 (22.58%)
    3 / 28 (10.71%)
    20 / 60 (33.33%)
    2 / 12 (16.67%)
    69 / 271 (25.46%)
         occurrences all number
    39
    9
    3
    23
    4
    81
    Malaise
         subjects affected / exposed
    5 / 201 (2.49%)
    0 / 31 (0.00%)
    1 / 28 (3.57%)
    5 / 60 (8.33%)
    0 / 12 (0.00%)
    4 / 271 (1.48%)
         occurrences all number
    5
    0
    3
    5
    0
    4
    Mucosal inflammation
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    4 / 60 (6.67%)
    0 / 12 (0.00%)
    12 / 271 (4.43%)
         occurrences all number
    2
    0
    0
    4
    0
    14
    Asthenia
         subjects affected / exposed
    24 / 201 (11.94%)
    3 / 31 (9.68%)
    0 / 28 (0.00%)
    2 / 60 (3.33%)
    1 / 12 (8.33%)
    30 / 271 (11.07%)
         occurrences all number
    59
    3
    0
    2
    1
    43
    Early satiety
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences all number
    1
    0
    0
    0
    1
    0
    Face oedema
         subjects affected / exposed
    2 / 201 (1.00%)
    2 / 31 (6.45%)
    1 / 28 (3.57%)
    2 / 60 (3.33%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences all number
    2
    2
    1
    2
    0
    3
    Facial pain
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    Influenza like illness
         subjects affected / exposed
    7 / 201 (3.48%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    9 / 60 (15.00%)
    0 / 12 (0.00%)
    11 / 271 (4.06%)
         occurrences all number
    12
    0
    0
    12
    0
    16
    Local swelling
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    3 / 271 (1.11%)
         occurrences all number
    0
    0
    0
    0
    1
    3
    Non-cardiac chest pain
         subjects affected / exposed
    6 / 201 (2.99%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    2 / 60 (3.33%)
    2 / 12 (16.67%)
    4 / 271 (1.48%)
         occurrences all number
    8
    0
    0
    2
    3
    4
    Peripheral swelling
         subjects affected / exposed
    1 / 201 (0.50%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    3 / 271 (1.11%)
         occurrences all number
    1
    1
    0
    0
    1
    4
    Pyrexia
         subjects affected / exposed
    20 / 201 (9.95%)
    1 / 31 (3.23%)
    2 / 28 (7.14%)
    12 / 60 (20.00%)
    2 / 12 (16.67%)
    32 / 271 (11.81%)
         occurrences all number
    25
    1
    2
    13
    2
    35
    Oedema peripheral
         subjects affected / exposed
    20 / 201 (9.95%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    5 / 60 (8.33%)
    2 / 12 (16.67%)
    27 / 271 (9.96%)
         occurrences all number
    23
    0
    0
    7
    4
    29
    Reproductive system and breast disorders
    Benign prostatic hyperplasia
         subjects affected / exposed
    6 / 201 (2.99%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    1 / 12 (8.33%)
    5 / 271 (1.85%)
         occurrences all number
    6
    1
    0
    1
    1
    5
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea
         subjects affected / exposed
    32 / 201 (15.92%)
    2 / 31 (6.45%)
    1 / 28 (3.57%)
    7 / 60 (11.67%)
    5 / 12 (41.67%)
    49 / 271 (18.08%)
         occurrences all number
    35
    3
    1
    10
    6
    59
    Dysphonia
         subjects affected / exposed
    4 / 201 (1.99%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    2 / 12 (16.67%)
    13 / 271 (4.80%)
         occurrences all number
    4
    0
    0
    0
    2
    13
    Cough
         subjects affected / exposed
    51 / 201 (25.37%)
    4 / 31 (12.90%)
    1 / 28 (3.57%)
    17 / 60 (28.33%)
    3 / 12 (25.00%)
    71 / 271 (26.20%)
         occurrences all number
    62
    4
    1
    25
    3
    87
    Aspiration
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences all number
    1
    0
    0
    0
    1
    1
    Epistaxis
         subjects affected / exposed
    12 / 201 (5.97%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    9 / 60 (15.00%)
    1 / 12 (8.33%)
    15 / 271 (5.54%)
         occurrences all number
    14
    1
    0
    11
    2
    17
    Rhinorrhoea
         subjects affected / exposed
    7 / 201 (3.48%)
    2 / 31 (6.45%)
    0 / 28 (0.00%)
    7 / 60 (11.67%)
    2 / 12 (16.67%)
    24 / 271 (8.86%)
         occurrences all number
    8
    3
    0
    8
    2
    26
    Haemoptysis
         subjects affected / exposed
    10 / 201 (4.98%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    5 / 60 (8.33%)
    1 / 12 (8.33%)
    8 / 271 (2.95%)
         occurrences all number
    12
    0
    0
    5
    2
    8
    Hypoxia
         subjects affected / exposed
    4 / 201 (1.99%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    3 / 12 (25.00%)
    1 / 271 (0.37%)
         occurrences all number
    4
    0
    0
    1
    5
    1
    Nasal discomfort
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    Nasal inflammation
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    2 / 271 (0.74%)
         occurrences all number
    2
    0
    0
    0
    1
    4
    Oropharyngeal pain
         subjects affected / exposed
    9 / 201 (4.48%)
    4 / 31 (12.90%)
    0 / 28 (0.00%)
    4 / 60 (6.67%)
    3 / 12 (25.00%)
    12 / 271 (4.43%)
         occurrences all number
    9
    4
    0
    5
    4
    13
    Paranasal sinus discomfort
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences all number
    1
    0
    0
    0
    1
    0
    Pleural effusion
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    1 / 12 (8.33%)
    4 / 271 (1.48%)
         occurrences all number
    2
    0
    0
    1
    1
    5
    Pneumonia aspiration
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences all number
    2
    0
    0
    0
    1
    1
    Pneumonitis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    1 / 28 (3.57%)
    1 / 60 (1.67%)
    1 / 12 (8.33%)
    3 / 271 (1.11%)
         occurrences all number
    0
    0
    1
    1
    1
    3
    Productive cough
         subjects affected / exposed
    12 / 201 (5.97%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    12 / 271 (4.43%)
         occurrences all number
    15
    1
    0
    0
    1
    13
    Pulmonary embolism
         subjects affected / exposed
    8 / 201 (3.98%)
    3 / 31 (9.68%)
    2 / 28 (7.14%)
    3 / 60 (5.00%)
    2 / 12 (16.67%)
    11 / 271 (4.06%)
         occurrences all number
    8
    4
    2
    3
    2
    11
    Rhinitis allergic
         subjects affected / exposed
    9 / 201 (4.48%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    2 / 60 (3.33%)
    1 / 12 (8.33%)
    6 / 271 (2.21%)
         occurrences all number
    9
    1
    0
    2
    1
    6
    Sinus congestion
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    Sneezing
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    Wheezing
         subjects affected / exposed
    3 / 201 (1.49%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    5 / 271 (1.85%)
         occurrences all number
    4
    0
    0
    0
    1
    5
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    9 / 201 (4.48%)
    0 / 31 (0.00%)
    1 / 28 (3.57%)
    4 / 60 (6.67%)
    2 / 12 (16.67%)
    13 / 271 (4.80%)
         occurrences all number
    9
    0
    1
    4
    2
    14
    Confusional state
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    Insomnia
         subjects affected / exposed
    30 / 201 (14.93%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    12 / 60 (20.00%)
    3 / 12 (25.00%)
    30 / 271 (11.07%)
         occurrences all number
    35
    1
    0
    16
    3
    32
    Depressed mood
         subjects affected / exposed
    1 / 201 (0.50%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    5 / 271 (1.85%)
         occurrences all number
    1
    1
    0
    0
    1
    6
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    18 / 201 (8.96%)
    4 / 31 (12.90%)
    1 / 28 (3.57%)
    7 / 60 (11.67%)
    0 / 12 (0.00%)
    18 / 271 (6.64%)
         occurrences all number
    24
    4
    1
    10
    0
    27
    Aspartate aminotransferase increased
         subjects affected / exposed
    16 / 201 (7.96%)
    2 / 31 (6.45%)
    1 / 28 (3.57%)
    6 / 60 (10.00%)
    0 / 12 (0.00%)
    21 / 271 (7.75%)
         occurrences all number
    25
    2
    1
    11
    0
    31
    Blood alkaline phosphatase increased
         subjects affected / exposed
    9 / 201 (4.48%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    3 / 60 (5.00%)
    0 / 12 (0.00%)
    15 / 271 (5.54%)
         occurrences all number
    9
    0
    0
    3
    0
    15
    Blood creatinine increased
         subjects affected / exposed
    13 / 201 (6.47%)
    2 / 31 (6.45%)
    1 / 28 (3.57%)
    3 / 60 (5.00%)
    0 / 12 (0.00%)
    13 / 271 (4.80%)
         occurrences all number
    18
    3
    1
    4
    0
    19
    Computerised tomogram thorax abnormal
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    3 / 12 (25.00%)
    0 / 271 (0.00%)
         occurrences all number
    1
    0
    0
    1
    3
    0
    Electrocardiogram qt prolonged
         subjects affected / exposed
    7 / 201 (3.48%)
    0 / 31 (0.00%)
    5 / 28 (17.86%)
    5 / 60 (8.33%)
    1 / 12 (8.33%)
    10 / 271 (3.69%)
         occurrences all number
    21
    0
    5
    5
    1
    11
    White blood cell count decreased
         subjects affected / exposed
    18 / 201 (8.96%)
    3 / 31 (9.68%)
    6 / 28 (21.43%)
    12 / 60 (20.00%)
    0 / 12 (0.00%)
    11 / 271 (4.06%)
         occurrences all number
    30
    4
    16
    25
    0
    25
    Renal function test abnormal
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    2 / 12 (16.67%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    Platelet count decreased
         subjects affected / exposed
    33 / 201 (16.42%)
    1 / 31 (3.23%)
    3 / 28 (10.71%)
    13 / 60 (21.67%)
    0 / 12 (0.00%)
    26 / 271 (9.59%)
         occurrences all number
    62
    2
    8
    18
    0
    39
    Neutrophil count decreased
         subjects affected / exposed
    15 / 201 (7.46%)
    3 / 31 (9.68%)
    6 / 28 (21.43%)
    6 / 60 (10.00%)
    0 / 12 (0.00%)
    19 / 271 (7.01%)
         occurrences all number
    21
    6
    27
    9
    0
    47
    Lymphocyte count decreased
         subjects affected / exposed
    6 / 201 (2.99%)
    0 / 31 (0.00%)
    2 / 28 (7.14%)
    3 / 60 (5.00%)
    0 / 12 (0.00%)
    7 / 271 (2.58%)
         occurrences all number
    7
    0
    23
    3
    0
    8
    Glycosylated haemoglobin increased
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    Weight decreased
         subjects affected / exposed
    12 / 201 (5.97%)
    2 / 31 (6.45%)
    3 / 28 (10.71%)
    14 / 60 (23.33%)
    1 / 12 (8.33%)
    26 / 271 (9.59%)
         occurrences all number
    14
    2
    3
    15
    1
    26
    Injury, poisoning and procedural complications
    Contusion
         subjects affected / exposed
    3 / 201 (1.49%)
    0 / 31 (0.00%)
    1 / 28 (3.57%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    4 / 271 (1.48%)
         occurrences all number
    3
    0
    1
    0
    1
    5
    Muscle strain
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences all number
    1
    0
    0
    0
    1
    1
    Procedural pain
         subjects affected / exposed
    6 / 201 (2.99%)
    0 / 31 (0.00%)
    2 / 28 (7.14%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences all number
    6
    0
    2
    0
    0
    3
    Rib fracture
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences all number
    1
    0
    0
    0
    1
    0
    Traumatic fracture
         subjects affected / exposed
    4 / 201 (1.99%)
    3 / 31 (9.68%)
    0 / 28 (0.00%)
    2 / 60 (3.33%)
    0 / 12 (0.00%)
    4 / 271 (1.48%)
         occurrences all number
    4
    3
    0
    2
    0
    5
    Cardiac disorders
    Palpitations
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    3 / 60 (5.00%)
    1 / 12 (8.33%)
    2 / 271 (0.74%)
         occurrences all number
    2
    0
    0
    3
    1
    2
    Pericardial effusion
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    Supraventricular tachycardia
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    2 / 271 (0.74%)
         occurrences all number
    1
    0
    0
    0
    1
    2
    Nervous system disorders
    Aphasia
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    1 / 12 (8.33%)
    4 / 271 (1.48%)
         occurrences all number
    1
    0
    0
    1
    1
    5
    Visual field defect
         subjects affected / exposed
    1 / 201 (0.50%)
    2 / 31 (6.45%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    1
    2
    0
    0
    0
    1
    Tremor
         subjects affected / exposed
    3 / 201 (1.49%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    1 / 12 (8.33%)
    2 / 271 (0.74%)
         occurrences all number
    3
    0
    0
    1
    2
    2
    Transient ischaemic attack
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    Peripheral sensory neuropathy
         subjects affected / exposed
    3 / 201 (1.49%)
    2 / 31 (6.45%)
    0 / 28 (0.00%)
    3 / 60 (5.00%)
    0 / 12 (0.00%)
    8 / 271 (2.95%)
         occurrences all number
    3
    2
    0
    6
    0
    11
    Paraesthesia
         subjects affected / exposed
    4 / 201 (1.99%)
    3 / 31 (9.68%)
    0 / 28 (0.00%)
    4 / 60 (6.67%)
    0 / 12 (0.00%)
    9 / 271 (3.32%)
         occurrences all number
    8
    3
    0
    4
    0
    10
    Headache
         subjects affected / exposed
    30 / 201 (14.93%)
    6 / 31 (19.35%)
    1 / 28 (3.57%)
    9 / 60 (15.00%)
    1 / 12 (8.33%)
    40 / 271 (14.76%)
         occurrences all number
    35
    9
    1
    14
    6
    50
    Dysgeusia
         subjects affected / exposed
    5 / 201 (2.49%)
    3 / 31 (9.68%)
    2 / 28 (7.14%)
    10 / 60 (16.67%)
    1 / 12 (8.33%)
    15 / 271 (5.54%)
         occurrences all number
    5
    3
    2
    12
    1
    17
    Dysarthria
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    1 / 12 (8.33%)
    3 / 271 (1.11%)
         occurrences all number
    0
    0
    0
    1
    1
    3
    Dizziness
         subjects affected / exposed
    16 / 201 (7.96%)
    3 / 31 (9.68%)
    0 / 28 (0.00%)
    9 / 60 (15.00%)
    2 / 12 (16.67%)
    27 / 271 (9.96%)
         occurrences all number
    18
    3
    0
    9
    3
    34
    Carotid artery aneurysm
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    34 / 201 (16.92%)
    7 / 31 (22.58%)
    6 / 28 (21.43%)
    16 / 60 (26.67%)
    1 / 12 (8.33%)
    41 / 271 (15.13%)
         occurrences all number
    42
    8
    16
    18
    1
    60
    Leukopenia
         subjects affected / exposed
    10 / 201 (4.98%)
    1 / 31 (3.23%)
    4 / 28 (14.29%)
    4 / 60 (6.67%)
    0 / 12 (0.00%)
    10 / 271 (3.69%)
         occurrences all number
    14
    1
    12
    7
    0
    22
    Lymphadenopathy
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    Lymphopenia
         subjects affected / exposed
    7 / 201 (3.48%)
    1 / 31 (3.23%)
    2 / 28 (7.14%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    6 / 271 (2.21%)
         occurrences all number
    11
    1
    3
    1
    0
    9
    Thrombocytopenia
         subjects affected / exposed
    16 / 201 (7.96%)
    2 / 31 (6.45%)
    2 / 28 (7.14%)
    7 / 60 (11.67%)
    2 / 12 (16.67%)
    23 / 271 (8.49%)
         occurrences all number
    19
    2
    3
    12
    2
    34
    Neutropenia
         subjects affected / exposed
    14 / 201 (6.97%)
    4 / 31 (12.90%)
    5 / 28 (17.86%)
    6 / 60 (10.00%)
    0 / 12 (0.00%)
    15 / 271 (5.54%)
         occurrences all number
    22
    8
    14
    14
    0
    18
    Ear and labyrinth disorders
    Tinnitus
         subjects affected / exposed
    3 / 201 (1.49%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    1 / 12 (8.33%)
    4 / 271 (1.48%)
         occurrences all number
    3
    0
    0
    1
    1
    4
    Hypoacusis
         subjects affected / exposed
    3 / 201 (1.49%)
    2 / 31 (6.45%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    2 / 12 (16.67%)
    8 / 271 (2.95%)
         occurrences all number
    3
    2
    0
    1
    2
    8
    Vertigo
         subjects affected / exposed
    4 / 201 (1.99%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    2 / 60 (3.33%)
    1 / 12 (8.33%)
    3 / 271 (1.11%)
         occurrences all number
    5
    0
    0
    2
    1
    4
    Eye disorders
    Blepharitis
         subjects affected / exposed
    2 / 201 (1.00%)
    2 / 31 (6.45%)
    0 / 28 (0.00%)
    4 / 60 (6.67%)
    0 / 12 (0.00%)
    5 / 271 (1.85%)
         occurrences all number
    2
    2
    0
    4
    0
    6
    Cataract
         subjects affected / exposed
    3 / 201 (1.49%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    3 / 60 (5.00%)
    1 / 12 (8.33%)
    6 / 271 (2.21%)
         occurrences all number
    5
    0
    0
    3
    1
    7
    Conjunctival haemorrhage
         subjects affected / exposed
    3 / 201 (1.49%)
    2 / 31 (6.45%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    4 / 271 (1.48%)
         occurrences all number
    4
    2
    0
    1
    0
    6
    Dry eye
         subjects affected / exposed
    14 / 201 (6.97%)
    4 / 31 (12.90%)
    1 / 28 (3.57%)
    7 / 60 (11.67%)
    1 / 12 (8.33%)
    20 / 271 (7.38%)
         occurrences all number
    32
    8
    2
    14
    2
    42
    Eye discharge
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    2 / 28 (7.14%)
    2 / 60 (3.33%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    2
    2
    0
    1
    Visual acuity reduced
         subjects affected / exposed
    2 / 201 (1.00%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    1 / 12 (8.33%)
    3 / 271 (1.11%)
         occurrences all number
    2
    1
    0
    1
    1
    3
    Eyelid oedema
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    1 / 12 (8.33%)
    2 / 271 (0.74%)
         occurrences all number
    0
    0
    0
    1
    1
    2
    Lacrimation increased
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    3 / 271 (1.11%)
         occurrences all number
    2
    0
    0
    0
    1
    3
    Macular degeneration
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    Photopsia
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    0
    1
    2
    1
    Vision blurred
         subjects affected / exposed
    6 / 201 (2.99%)
    2 / 31 (6.45%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    5 / 271 (1.85%)
         occurrences all number
    6
    3
    0
    1
    0
    5
    Eye disorder
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    Visual impairment
         subjects affected / exposed
    6 / 201 (2.99%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    3 / 60 (5.00%)
    1 / 12 (8.33%)
    2 / 271 (0.74%)
         occurrences all number
    7
    0
    0
    3
    2
    2
    Vitreous detachment
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences all number
    1
    0
    0
    0
    1
    0
    Vitreous floaters
         subjects affected / exposed
    3 / 201 (1.49%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    1 / 12 (8.33%)
    4 / 271 (1.48%)
         occurrences all number
    3
    0
    0
    1
    1
    5
    Gastrointestinal disorders
    Vomiting
         subjects affected / exposed
    35 / 201 (17.41%)
    8 / 31 (25.81%)
    4 / 28 (14.29%)
    14 / 60 (23.33%)
    1 / 12 (8.33%)
    53 / 271 (19.56%)
         occurrences all number
    51
    11
    5
    19
    1
    92
    Anal incontinence
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    Abdominal discomfort
         subjects affected / exposed
    7 / 201 (3.48%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    1 / 12 (8.33%)
    5 / 271 (1.85%)
         occurrences all number
    7
    1
    0
    1
    2
    5
    Abdominal distension
         subjects affected / exposed
    6 / 201 (2.99%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    4 / 60 (6.67%)
    2 / 12 (16.67%)
    13 / 271 (4.80%)
         occurrences all number
    6
    0
    0
    6
    3
    16
    Abdominal pain
         subjects affected / exposed
    15 / 201 (7.46%)
    3 / 31 (9.68%)
    0 / 28 (0.00%)
    4 / 60 (6.67%)
    0 / 12 (0.00%)
    30 / 271 (11.07%)
         occurrences all number
    16
    3
    0
    4
    0
    33
    Dyschezia
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    Chapped lips
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    Cheilitis
         subjects affected / exposed
    1 / 201 (0.50%)
    1 / 31 (3.23%)
    3 / 28 (10.71%)
    2 / 60 (3.33%)
    0 / 12 (0.00%)
    4 / 271 (1.48%)
         occurrences all number
    1
    1
    3
    2
    0
    4
    Constipation
         subjects affected / exposed
    52 / 201 (25.87%)
    3 / 31 (9.68%)
    5 / 28 (17.86%)
    25 / 60 (41.67%)
    2 / 12 (16.67%)
    70 / 271 (25.83%)
         occurrences all number
    60
    4
    5
    28
    2
    83
    Diarrhoea
         subjects affected / exposed
    103 / 201 (51.24%)
    19 / 31 (61.29%)
    10 / 28 (35.71%)
    43 / 60 (71.67%)
    5 / 12 (41.67%)
    152 / 271 (56.09%)
         occurrences all number
    270
    44
    14
    82
    7
    259
    Dry mouth
         subjects affected / exposed
    14 / 201 (6.97%)
    1 / 31 (3.23%)
    1 / 28 (3.57%)
    6 / 60 (10.00%)
    0 / 12 (0.00%)
    17 / 271 (6.27%)
         occurrences all number
    14
    1
    1
    6
    0
    18
    Abdominal pain upper
         subjects affected / exposed
    16 / 201 (7.96%)
    3 / 31 (9.68%)
    1 / 28 (3.57%)
    13 / 60 (21.67%)
    0 / 12 (0.00%)
    21 / 271 (7.75%)
         occurrences all number
    27
    4
    1
    17
    0
    29
    Dyspepsia
         subjects affected / exposed
    15 / 201 (7.46%)
    4 / 31 (12.90%)
    0 / 28 (0.00%)
    6 / 60 (10.00%)
    1 / 12 (8.33%)
    19 / 271 (7.01%)
         occurrences all number
    15
    4
    0
    6
    1
    22
    Dysphagia
         subjects affected / exposed
    6 / 201 (2.99%)
    2 / 31 (6.45%)
    0 / 28 (0.00%)
    2 / 60 (3.33%)
    1 / 12 (8.33%)
    11 / 271 (4.06%)
         occurrences all number
    8
    3
    0
    2
    1
    11
    Flatulence
         subjects affected / exposed
    3 / 201 (1.49%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    6 / 271 (2.21%)
         occurrences all number
    3
    2
    0
    0
    1
    6
    Gastritis
         subjects affected / exposed
    4 / 201 (1.99%)
    0 / 31 (0.00%)
    1 / 28 (3.57%)
    6 / 60 (10.00%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences all number
    5
    0
    1
    6
    0
    3
    Gastrooesophageal reflux disease
         subjects affected / exposed
    8 / 201 (3.98%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    8 / 60 (13.33%)
    2 / 12 (16.67%)
    11 / 271 (4.06%)
         occurrences all number
    8
    1
    0
    9
    2
    12
    Haemorrhoids
         subjects affected / exposed
    5 / 201 (2.49%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    6 / 60 (10.00%)
    0 / 12 (0.00%)
    6 / 271 (2.21%)
         occurrences all number
    5
    1
    0
    7
    0
    6
    Mouth ulceration
         subjects affected / exposed
    5 / 201 (2.49%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    8 / 60 (13.33%)
    0 / 12 (0.00%)
    8 / 271 (2.95%)
         occurrences all number
    5
    0
    0
    10
    0
    8
    Nausea
         subjects affected / exposed
    54 / 201 (26.87%)
    10 / 31 (32.26%)
    5 / 28 (17.86%)
    17 / 60 (28.33%)
    7 / 12 (58.33%)
    81 / 271 (29.89%)
         occurrences all number
    77
    11
    5
    28
    8
    113
    Oesophageal stenosis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    0
    0
    1
    2
    Stomatitis
         subjects affected / exposed
    35 / 201 (17.41%)
    8 / 31 (25.81%)
    10 / 28 (35.71%)
    30 / 60 (50.00%)
    1 / 12 (8.33%)
    57 / 271 (21.03%)
         occurrences all number
    45
    14
    15
    62
    1
    79
    Toothache
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    1 / 12 (8.33%)
    6 / 271 (2.21%)
         occurrences all number
    2
    0
    0
    1
    2
    6
    Lip pain
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    Skin and subcutaneous tissue disorders
    Onychoclasis
         subjects affected / exposed
    13 / 201 (6.47%)
    1 / 31 (3.23%)
    1 / 28 (3.57%)
    3 / 60 (5.00%)
    3 / 12 (25.00%)
    7 / 271 (2.58%)
         occurrences all number
    13
    1
    1
    3
    3
    7
    Nail disorder
         subjects affected / exposed
    6 / 201 (2.99%)
    3 / 31 (9.68%)
    3 / 28 (10.71%)
    3 / 60 (5.00%)
    1 / 12 (8.33%)
    11 / 271 (4.06%)
         occurrences all number
    8
    3
    3
    3
    1
    12
    Nail discolouration
         subjects affected / exposed
    5 / 201 (2.49%)
    2 / 31 (6.45%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    6
    2
    0
    1
    0
    1
    Erythema
         subjects affected / exposed
    9 / 201 (4.48%)
    1 / 31 (3.23%)
    2 / 28 (7.14%)
    3 / 60 (5.00%)
    0 / 12 (0.00%)
    12 / 271 (4.43%)
         occurrences all number
    9
    1
    2
    3
    0
    14
    Eczema
         subjects affected / exposed
    3 / 201 (1.49%)
    1 / 31 (3.23%)
    2 / 28 (7.14%)
    5 / 60 (8.33%)
    0 / 12 (0.00%)
    4 / 271 (1.48%)
         occurrences all number
    3
    2
    2
    5
    0
    4
    Ecchymosis
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences all number
    1
    0
    0
    0
    1
    1
    Dry skin
         subjects affected / exposed
    53 / 201 (26.37%)
    9 / 31 (29.03%)
    12 / 28 (42.86%)
    26 / 60 (43.33%)
    4 / 12 (33.33%)
    64 / 271 (23.62%)
         occurrences all number
    57
    9
    12
    34
    4
    80
    Dermatitis acneiform
         subjects affected / exposed
    17 / 201 (8.46%)
    3 / 31 (9.68%)
    2 / 28 (7.14%)
    18 / 60 (30.00%)
    1 / 12 (8.33%)
    41 / 271 (15.13%)
         occurrences all number
    22
    3
    2
    20
    1
    52
    Alopecia
         subjects affected / exposed
    8 / 201 (3.98%)
    1 / 31 (3.23%)
    2 / 28 (7.14%)
    5 / 60 (8.33%)
    2 / 12 (16.67%)
    12 / 271 (4.43%)
         occurrences all number
    10
    1
    2
    6
    2
    12
    Acne
         subjects affected / exposed
    4 / 201 (1.99%)
    0 / 31 (0.00%)
    1 / 28 (3.57%)
    4 / 60 (6.67%)
    0 / 12 (0.00%)
    12 / 271 (4.43%)
         occurrences all number
    10
    0
    1
    4
    0
    13
    Palmar erythema
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    Skin sensitisation
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences all number
    1
    0
    0
    0
    1
    0
    Skin irritation
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    Skin fissures
         subjects affected / exposed
    13 / 201 (6.47%)
    4 / 31 (12.90%)
    1 / 28 (3.57%)
    9 / 60 (15.00%)
    1 / 12 (8.33%)
    31 / 271 (11.44%)
         occurrences all number
    14
    6
    2
    9
    1
    33
    Skin exfoliation
         subjects affected / exposed
    2 / 201 (1.00%)
    2 / 31 (6.45%)
    1 / 28 (3.57%)
    3 / 60 (5.00%)
    0 / 12 (0.00%)
    15 / 271 (5.54%)
         occurrences all number
    2
    2
    1
    3
    0
    16
    Rash papular
         subjects affected / exposed
    4 / 201 (1.99%)
    0 / 31 (0.00%)
    2 / 28 (7.14%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences all number
    4
    0
    2
    2
    0
    4
    Rash macular
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    1 / 28 (3.57%)
    6 / 60 (10.00%)
    0 / 12 (0.00%)
    6 / 271 (2.21%)
         occurrences all number
    2
    0
    1
    8
    0
    6
    Rash erythematous
         subjects affected / exposed
    1 / 201 (0.50%)
    2 / 31 (6.45%)
    1 / 28 (3.57%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    6 / 271 (2.21%)
         occurrences all number
    1
    2
    1
    0
    0
    8
    Rash
         subjects affected / exposed
    53 / 201 (26.37%)
    10 / 31 (32.26%)
    4 / 28 (14.29%)
    22 / 60 (36.67%)
    3 / 12 (25.00%)
    76 / 271 (28.04%)
         occurrences all number
    66
    16
    4
    27
    3
    105
    Pruritus
         subjects affected / exposed
    36 / 201 (17.91%)
    8 / 31 (25.81%)
    4 / 28 (14.29%)
    16 / 60 (26.67%)
    3 / 12 (25.00%)
    61 / 271 (22.51%)
         occurrences all number
    49
    10
    4
    18
    4
    72
    Palmar-plantar erythrodysaesthesia syndrome
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    4 / 60 (6.67%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    1
    0
    0
    6
    0
    1
    Rash maculo-papular
         subjects affected / exposed
    11 / 201 (5.47%)
    3 / 31 (9.68%)
    1 / 28 (3.57%)
    7 / 60 (11.67%)
    1 / 12 (8.33%)
    12 / 271 (4.43%)
         occurrences all number
    17
    6
    1
    9
    2
    22
    Renal and urinary disorders
    Nephrolithiasis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    2 / 60 (3.33%)
    1 / 12 (8.33%)
    3 / 271 (1.11%)
         occurrences all number
    0
    0
    0
    2
    1
    3
    Hydronephrosis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    Haematuria
         subjects affected / exposed
    3 / 201 (1.49%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    6 / 271 (2.21%)
         occurrences all number
    3
    0
    0
    0
    1
    6
    Nocturia
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    3 / 271 (1.11%)
         occurrences all number
    1
    0
    0
    0
    1
    3
    Musculoskeletal and connective tissue disorders
    Neck pain
         subjects affected / exposed
    13 / 201 (6.47%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    8 / 271 (2.95%)
         occurrences all number
    13
    1
    0
    1
    0
    8
    Myalgia
         subjects affected / exposed
    15 / 201 (7.46%)
    2 / 31 (6.45%)
    1 / 28 (3.57%)
    4 / 60 (6.67%)
    3 / 12 (25.00%)
    17 / 271 (6.27%)
         occurrences all number
    15
    2
    1
    4
    4
    18
    Musculoskeletal pain
         subjects affected / exposed
    26 / 201 (12.94%)
    2 / 31 (6.45%)
    2 / 28 (7.14%)
    5 / 60 (8.33%)
    2 / 12 (16.67%)
    25 / 271 (9.23%)
         occurrences all number
    30
    2
    2
    5
    2
    26
    Musculoskeletal chest pain
         subjects affected / exposed
    14 / 201 (6.97%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    8 / 60 (13.33%)
    3 / 12 (25.00%)
    22 / 271 (8.12%)
         occurrences all number
    16
    0
    0
    10
    4
    23
    Muscular weakness
         subjects affected / exposed
    5 / 201 (2.49%)
    2 / 31 (6.45%)
    1 / 28 (3.57%)
    3 / 60 (5.00%)
    0 / 12 (0.00%)
    5 / 271 (1.85%)
         occurrences all number
    5
    2
    2
    3
    0
    6
    Muscle spasms
         subjects affected / exposed
    19 / 201 (9.45%)
    3 / 31 (9.68%)
    1 / 28 (3.57%)
    8 / 60 (13.33%)
    2 / 12 (16.67%)
    32 / 271 (11.81%)
         occurrences all number
    23
    4
    1
    10
    5
    38
    Muscle atrophy
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    2 / 12 (16.67%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    0
    0
    2
    1
    Back pain
         subjects affected / exposed
    41 / 201 (20.40%)
    5 / 31 (16.13%)
    3 / 28 (10.71%)
    9 / 60 (15.00%)
    2 / 12 (16.67%)
    38 / 271 (14.02%)
         occurrences all number
    52
    8
    3
    11
    2
    43
    Arthritis
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    1 / 28 (3.57%)
    1 / 60 (1.67%)
    1 / 12 (8.33%)
    3 / 271 (1.11%)
         occurrences all number
    1
    0
    1
    2
    1
    3
    Arthralgia
         subjects affected / exposed
    24 / 201 (11.94%)
    4 / 31 (12.90%)
    3 / 28 (10.71%)
    6 / 60 (10.00%)
    2 / 12 (16.67%)
    30 / 271 (11.07%)
         occurrences all number
    30
    4
    3
    7
    2
    46
    Pain in extremity
         subjects affected / exposed
    15 / 201 (7.46%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    5 / 60 (8.33%)
    4 / 12 (33.33%)
    30 / 271 (11.07%)
         occurrences all number
    16
    0
    0
    8
    7
    37
    Infections and infestations
    Oral herpes
         subjects affected / exposed
    3 / 201 (1.49%)
    2 / 31 (6.45%)
    2 / 28 (7.14%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    2 / 271 (0.74%)
         occurrences all number
    3
    2
    2
    0
    1
    2
    Cystitis
         subjects affected / exposed
    10 / 201 (4.98%)
    1 / 31 (3.23%)
    1 / 28 (3.57%)
    4 / 60 (6.67%)
    0 / 12 (0.00%)
    6 / 271 (2.21%)
         occurrences all number
    12
    1
    1
    5
    0
    8
    Abscess limb
         subjects affected / exposed
    1 / 201 (0.50%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences all number
    1
    0
    0
    0
    1
    0
    Bronchitis
         subjects affected / exposed
    9 / 201 (4.48%)
    2 / 31 (6.45%)
    1 / 28 (3.57%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    8 / 271 (2.95%)
         occurrences all number
    10
    2
    1
    1
    0
    10
    Conjunctivitis
         subjects affected / exposed
    11 / 201 (5.47%)
    1 / 31 (3.23%)
    2 / 28 (7.14%)
    8 / 60 (13.33%)
    0 / 12 (0.00%)
    5 / 271 (1.85%)
         occurrences all number
    20
    2
    2
    9
    0
    6
    Folliculitis
         subjects affected / exposed
    3 / 201 (1.49%)
    2 / 31 (6.45%)
    0 / 28 (0.00%)
    5 / 60 (8.33%)
    0 / 12 (0.00%)
    14 / 271 (5.17%)
         occurrences all number
    3
    2
    0
    5
    0
    15
    Gastroenteritis
         subjects affected / exposed
    3 / 201 (1.49%)
    0 / 31 (0.00%)
    2 / 28 (7.14%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    4 / 271 (1.48%)
         occurrences all number
    4
    0
    2
    1
    0
    4
    Lower respiratory tract infection
         subjects affected / exposed
    2 / 201 (1.00%)
    2 / 31 (6.45%)
    0 / 28 (0.00%)
    2 / 60 (3.33%)
    0 / 12 (0.00%)
    5 / 271 (1.85%)
         occurrences all number
    2
    7
    0
    2
    0
    8
    Lung infection
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    2 / 60 (3.33%)
    1 / 12 (8.33%)
    4 / 271 (1.48%)
         occurrences all number
    2
    0
    0
    3
    1
    4
    Lymphangitis
         subjects affected / exposed
    0 / 201 (0.00%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    0 / 60 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    Nasopharyngitis
         subjects affected / exposed
    18 / 201 (8.96%)
    7 / 31 (22.58%)
    3 / 28 (10.71%)
    4 / 60 (6.67%)
    1 / 12 (8.33%)
    25 / 271 (9.23%)
         occurrences all number
    24
    11
    3
    6
    1
    33
    Sinusitis
         subjects affected / exposed
    7 / 201 (3.48%)
    2 / 31 (6.45%)
    0 / 28 (0.00%)
    3 / 60 (5.00%)
    2 / 12 (16.67%)
    11 / 271 (4.06%)
         occurrences all number
    7
    2
    0
    3
    4
    15
    Pharyngitis
         subjects affected / exposed
    9 / 201 (4.48%)
    0 / 31 (0.00%)
    3 / 28 (10.71%)
    2 / 60 (3.33%)
    0 / 12 (0.00%)
    8 / 271 (2.95%)
         occurrences all number
    10
    0
    4
    2
    0
    8
    Pneumonia
         subjects affected / exposed
    9 / 201 (4.48%)
    1 / 31 (3.23%)
    1 / 28 (3.57%)
    6 / 60 (10.00%)
    0 / 12 (0.00%)
    11 / 271 (4.06%)
         occurrences all number
    11
    1
    1
    6
    0
    11
    Pneumonia bacterial
         subjects affected / exposed
    2 / 201 (1.00%)
    0 / 31 (0.00%)
    2 / 28 (7.14%)
    0 / 60 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    2
    0
    2
    0
    0
    1
    Rash pustular
         subjects affected / exposed
    5 / 201 (2.49%)
    1 / 31 (3.23%)
    0 / 28 (0.00%)
    3 / 60 (5.00%)
    2 / 12 (16.67%)
    4 / 271 (1.48%)
         occurrences all number
    9
    4
    0
    4
    2
    4
    Rhinitis
         subjects affected / exposed
    3 / 201 (1.49%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    1 / 60 (1.67%)
    1 / 12 (8.33%)
    3 / 271 (1.11%)
         occurrences all number
    3
    0
    0
    1
    1
    3
    Paronychia
         subjects affected / exposed
    56 / 201 (27.86%)
    8 / 31 (25.81%)
    11 / 28 (39.29%)
    28 / 60 (46.67%)
    2 / 12 (16.67%)
    71 / 271 (26.20%)
         occurrences all number
    74
    11
    12
    39
    3
    92
    Upper respiratory tract infection
         subjects affected / exposed
    31 / 201 (15.42%)
    7 / 31 (22.58%)
    5 / 28 (17.86%)
    16 / 60 (26.67%)
    4 / 12 (33.33%)
    33 / 271 (12.18%)
         occurrences all number
    45
    19
    7
    29
    4
    36
    Urinary tract infection
         subjects affected / exposed
    18 / 201 (8.96%)
    1 / 31 (3.23%)
    1 / 28 (3.57%)
    10 / 60 (16.67%)
    2 / 12 (16.67%)
    25 / 271 (9.23%)
         occurrences all number
    25
    1
    1
    17
    3
    32
    Metabolism and nutrition disorders
    Hypoalbuminaemia
         subjects affected / exposed
    5 / 201 (2.49%)
    0 / 31 (0.00%)
    2 / 28 (7.14%)
    3 / 60 (5.00%)
    0 / 12 (0.00%)
    12 / 271 (4.43%)
         occurrences all number
    6
    0
    2
    4
    0
    14
    Hyperkalaemia
         subjects affected / exposed
    5 / 201 (2.49%)
    1 / 31 (3.23%)
    3 / 28 (10.71%)
    1 / 60 (1.67%)
    0 / 12 (0.00%)
    9 / 271 (3.32%)
         occurrences all number
    8
    1
    3
    1
    0
    12
    Hyperglycaemia
         subjects affected / exposed
    6 / 201 (2.99%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    4 / 60 (6.67%)
    1 / 12 (8.33%)
    11 / 271 (4.06%)
         occurrences all number
    8
    0
    0
    7
    1
    22
    Dehydration
         subjects affected / exposed
    4 / 201 (1.99%)
    2 / 31 (6.45%)
    2 / 28 (7.14%)
    1 / 60 (1.67%)
    1 / 12 (8.33%)
    9 / 271 (3.32%)
         occurrences all number
    6
    3
    2
    2
    1
    10
    Decreased appetite
         subjects affected / exposed
    51 / 201 (25.37%)
    12 / 31 (38.71%)
    5 / 28 (17.86%)
    19 / 60 (31.67%)
    5 / 12 (41.67%)
    79 / 271 (29.15%)
         occurrences all number
    60
    18
    6
    20
    7
    95
    Hypocalcaemia
         subjects affected / exposed
    7 / 201 (3.48%)
    3 / 31 (9.68%)
    0 / 28 (0.00%)
    4 / 60 (6.67%)
    0 / 12 (0.00%)
    10 / 271 (3.69%)
         occurrences all number
    9
    3
    0
    4
    0
    14
    Hyponatraemia
         subjects affected / exposed
    10 / 201 (4.98%)
    0 / 31 (0.00%)
    0 / 28 (0.00%)
    6 / 60 (10.00%)
    0 / 12 (0.00%)
    17 / 271 (6.27%)
         occurrences all number
    10
    0
    0
    8
    0
    34
    Hypokalaemia
         subjects affected / exposed
    10 / 201 (4.98%)
    1 / 31 (3.23%)
    1 / 28 (3.57%)
    1 / 60 (1.67%)
    1 / 12 (8.33%)
    10 / 271 (3.69%)
         occurrences all number
    12
    2
    1
    1
    3
    13

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    Data cut on 01MAY2018 for final OS for extension cohort and final PFS, DoR and ORR for 1st line cohort. AEs used MedDRA 21.0. All remaining data/cohorts reported with a data cut of 01NOV2016. AEs used MedDRA 19.1. No comparisons as single arm.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 04:23:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA